drugset / Trial / NCT04514367
An Open Label Study of ANX005 in Subjects With, or at Risk for, Manifest Huntington's Disease
NaSingle-groupOpen-labelTreatment
Summary
This study is a multi-center, open-label study of intravenous (IV) ANX005 in subjects with, or at risk for, manifest Huntington's Disease (HD).
Timeline
- Start
- 2020-08-17
- Primary completion
- 2022-01-28
- Completion
- 2022-01-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ANX005 | Protein / enzyme biologic | — | Intravenous |